Nisa Investment Advisors LLC Has $21.54 Million Holdings in IDEXX Laboratories, Inc. $IDXX

Nisa Investment Advisors LLC cut its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 40,166 shares of the company’s stock after selling 52 shares during the quarter. Nisa Investment Advisors LLC’s holdings in IDEXX Laboratories were worth $21,543,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. MorganRosel Wealth Management LLC acquired a new position in shares of IDEXX Laboratories in the first quarter worth approximately $26,000. Opal Wealth Advisors LLC acquired a new position in shares of IDEXX Laboratories in the 2nd quarter worth approximately $29,000. Migdal Insurance & Financial Holdings Ltd. lifted its position in shares of IDEXX Laboratories by 55.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company’s stock worth $35,000 after purchasing an additional 30 shares during the period. Ameritas Advisory Services LLC acquired a new position in shares of IDEXX Laboratories in the 2nd quarter worth approximately $36,000. Finally, WPG Advisers LLC acquired a new position in shares of IDEXX Laboratories in the 1st quarter worth approximately $37,000. 87.84% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 2,187 shares of the firm’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the transaction, the director directly owned 262 shares in the company, valued at approximately $169,600.46. This trade represents a 89.30% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Sharon E. Underberg sold 5,450 shares of the firm’s stock in a transaction on Friday, August 8th. The shares were sold at an average price of $651.60, for a total value of $3,551,220.00. Following the transaction, the executive vice president owned 6,156 shares in the company, valued at approximately $4,011,249.60. This trade represents a 46.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 54,057 shares of company stock valued at $34,293,468. Corporate insiders own 0.98% of the company’s stock.

IDEXX Laboratories Stock Up 0.4%

IDXX stock opened at $640.85 on Monday. The stock’s 50 day simple moving average is $638.40 and its 200 day simple moving average is $560.29. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $688.12. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. The company has a market cap of $51.27 billion, a P/E ratio of 53.36, a price-to-earnings-growth ratio of 4.15 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, topping analysts’ consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The company had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same period in the prior year, the firm earned $2.44 earnings per share. IDEXX Laboratories’s revenue for the quarter was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, research analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. UBS Group assumed coverage on shares of IDEXX Laboratories in a report on Wednesday, October 1st. They issued a “neutral” rating and a $720.00 target price on the stock. Wall Street Zen downgraded IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Sunday, September 28th. Jefferies Financial Group started coverage on IDEXX Laboratories in a research note on Tuesday, July 1st. They issued a “buy” rating and a $625.00 price objective on the stock. BTIG Research boosted their price target on IDEXX Laboratories from $545.00 to $785.00 and gave the company a “buy” rating in a research note on Tuesday, August 5th. Finally, Stifel Nicolaus set a $640.00 price target on IDEXX Laboratories in a research note on Monday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $656.50.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.